Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhC1INH for Acute HAE Attacks
NCT00261053Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Jun 2003
- Primary completion
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of conestat alfa in hereditary angioedema (HAE), sponsored by Pharming Group. Started Jun 2003; status: completed.
02
Drugs
conestat alfa
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00261053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261053.